Agilent Says Companion Diagnostic Gets Expanded FDA Approval
July 31 2019 - 3:15PM
Dow Jones News
By Michael Dabaie
Agilent Technologies Inc. (A) said the U.S. Food and Drug
Administration has approved the company's companion diagnostic
PD-L1 IHC 22C3 pharmDx assay for expanded use.
The assay is now approved as an aid in identifying patients with
Esophageal Squamous Cell Carcinoma for treatment with Keytruda,
which is made by Merck & Co. Inc. (MRK).
This is the sixth cancer type for which PD-L1 IHC 22C3 pharmDx
has gained FDA approval in the U.S., Agilent said. Agilent
developed PD-L1 IHC 22C3 pharmDx in collaboration with Merck.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 31, 2019 15:00 ET (19:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024
